We are live on ! Find out more
MTRI icon

Mentari Therapeutics, Inc. Common Stock

7 hedge funds and large institutions have $117K invested in Mentari Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

6.05% less ownership

Funds ownership: 11.32% → 5.27% (-6.1%)

13% less funds holding

Funds holding: 8 → 7 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

73% less capital inflows, than outflows

Capital inflows: $34.4K | Capital outflows: $129K

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
7
Holders Change
-1
Holders Change %
-12.5%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

MTRI Hedge Fund Activity: Q2 2024 in Review

7 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Mentari Therapeutics, Inc. Common Stock (MTRI) for Q2 2024, worth a combined $117K — down 53% from $249K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of MTRI and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.

The largest buyer was Virtu Financial, opening a new position worth an estimated $24.7K. The largest seller was Armistice Capital, exiting entirely with an estimated $97.2K sold.

  • 7 institutional investors held Mentari Therapeutics, Inc. Common Stock (MTRI) as of Q2 2024, down from 8 in Q1 2024.
  • Funds reported $117K of Mentari Therapeutics, Inc. Common Stock stock for Q2 2024, down 53% quarter-over-quarter.
  • 3 funds opened new Mentari Therapeutics, Inc. Common Stock positions in Q2 2024 and 4 closed out, a net change of -1 holder.
  • The largest Mentari Therapeutics, Inc. Common Stock buyer in Q2 2024 was Virtu Financial, an estimated $24.7K added.
  • The largest Mentari Therapeutics, Inc. Common Stock seller in Q2 2024 was Armistice Capital, an estimated $97.2K sold.

Based on aggregated 13F filings for Q2 2024.